ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

lebrikizumab

Also written as “Lebrikizumab”, “lebrikizumab (MILR1444A)” and “LY3650150”.

Its studies are mostly in Dermatitis, Atopic · Asthma · Nasal Polyps · Rhinitis, Allergic, Perennial · Pulmonary Disease, Chronic Obstructive, led by 4 companies.

Drug pageLebrikizumab: every studyAll 48 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since May 28, 202544 company-led studies, 7 open or runningNext primary completion: Apr 25, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lillyits history only194 open or runningphase 4since May 28, 2025Feb 16, 2018May 2027phase 3 · NCT06338995
Hoffmann-La Rocheits history only180 open or runningphase 3since May 29, 2013Oct 27, 2008none ahead
Almirallits history only63 open or runningphase 3since Nov 26, 2021Nov 26, 2021Apr 25, 2027phase 3 · NCT06526182
Tanox10 open or runningphase 2since May 17, 2006May 17, 2006none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Tanox only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 17, 2006First study: phase 2 study in Hodgkin DiseaseFirst studyNCT00441818 · 59 enrolled · United States

TargetBeta

IL13 →read by rule
“A humanized monoclonal antibody against interleukin 13 (IL-13) with immunosuppressive and anti-asthmatic activities”NCIt, by rule
“Interleukin-13 inhibitor; Interleukin-13 inhibitor”ChEMBL 37, by rule

Other programs on IL13

ProgramCompanyFurthest phaseStudies
tilrekimigPfizerphase 311
lunsekimigSanofiphase 310
zumilokibartAbbViephase 24
ompekimigPfizerphase 23
GHZ339Novartisphase 21
ABBV-313AbbViephase 11

Studies

The one study Tanox leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00441818Hodgkin Disease · United States2UNKNOWN59

How it is read

Names in the registry

  • “Lebrikizumab”, 37 entries
  • “lebrikizumab”, 7 entries
  • “lebrikizumab (MILR1444A)”, 5 entries
  • “LY3650150”, 2 entries
  • “TNX-650”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.